Aventis Pharma: OPM disappointment continues… - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aventis Pharma: OPM disappointment continues…

Oct 31, 2002

Aventis Pharma, has reported nearly 13% topline growth for 3QFY03 on the back of strong performance of its strategic brands and jump in exports to CIS countries. The results for the relevant period under review are on a merged basis with RPR (Rhone Poulenc Rorer) and hence not exactly comparable on a like to like basis with the previous year numbers.

(Rs m)3QFY023QFY03% Change9mFY029mFY03% Change
Net Sales 1,412 1,592 12.7% 3,802 4,516 18.8%
Other Income 26 31 19.2% 81 72 -11.1%
Expenditure 1,141 1,328 16.4% 3,097 3,810 23.0%
Operating Profit (EBDIT) 271 264 -2.6% 705 706 0.1%
Operating Profit Margin (%)19.2%16.6%  18.5%15.6% 
Interest 4 1 -75.0% 15 4 -73.3%
Depreciation 38 38 0.0% 113 112 -0.9%
Profit before Tax 255 256 0.4% 658 662 0.6%
Extraordinary Expenses (VRS) (39) (5)- 31 (4)-
Tax 64 85 32.8% 213 215 0.9%
Profit after Tax/(Loss) 152 166 9.2% 476 443 -6.9%
Net profit margin (%)10.8%10.4% 12.5%9.8% 
No. of Shares (eoy) (m) 23 23   23 23  
Diluted Earnings per share*26.428.9 27.625.7 
P/E (at current price)  11.1    12.5  
(*- annualised)      

Domestic sales have grown by 9% from Rs 1.2 bn to Rs 1.3 bn including Rs 96 m from merger of RPR business. The performance has been on the back of strong growth in strategic products such as cardace (20% - cardiovascular), Amaryl (34% - anti-diabetes) and Targocid (29% - anti-infective). In addition, Clexane, acquired from RPR grew by a strong 41% during the quarter. Formulations exports sales (mainly to CIS countries) have recorded a growth of more than 20%.The company’s Ankleshwar unit is being used by the parent as a sourcing base for bulk drugs like Ramipril and Articaine. Further, the company has indicated that the parent has initiated steps to import Daonil formulations (a leading product in anti-diabetic segment) from India. Exports currently account for about 20% of the company’s revenues with Russia and CIS countries accounting for about 85% of the total export pie.

Despite strong sales growth, operating margins have been playing a spoilsport. Operating margins dropped from 19.2% in 3QFY02 to 16.6% this September quarter. Though the company's products enjoy a strong brand equity, it faces stiff competition from generic products. Raw material consumption to sales ratio indicates a drop in realisations for the company's products. Further, operating margins have also been affected on account of front loading of marketing expenses for products (Lantus and Actonel) expected to be launched in the next year. The company has stated that they expect these product promotion expenses to decline in the coming quarters.

Cost break-up
(Rs m)3QFY023QFY03% Change9mFY029mFY03% Change
Raw material 74488619.1%1,9492,42524.4%
Staff cost1141194.4%32938316.4%
Others28332314.1%8191,00222.3%
Total Expenditure1,1411,32816.4%3,0973,81023.0%

At the current market price of Rs 320, the stock trades at 9.7x our expected earnings for FY03. On the back of the support extended by the parent, Aventis has transformed itself from a company catering mainly to the anti-infectives and pain management segments to a company with a strong and focused portfolio of products for the chronic and critical-care therapeutic segments. The strategic brands continue to grow at healthy growth rates and this is expected to offset the impact of the laggards in its folio. This portfolio bias is expected to continue in the foreseeable future as well. Notwithstanding some unclarity on the impact of the DPCO order, valuations of the company are attractive on a peer comparision basis.

Equitymaster requests your view! Post a comment on "Aventis Pharma: OPM disappointment continues…". Click here!

  

More Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

Jubilant Pharmova Drops 6% on Weak March Quarter Numbers (Views On News)

Jun 8, 2021

Here's a rundown on the latest quarterly results of Jubilant Pharmova.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

Don't Break These 5 Intraday Trading Rules (Fast Profits Daily)

Jun 1, 2021

To become a better intraday trader, follow these rules religiously.

Is the RBI's 'Bubble Talk' Signalling a Market Crash? (Profit Hunter)

May 31, 2021

Is the Indian central bank correct in warning you about a market crash?

Rs 2 Trillion Stimulus Coming to a Stock Market Near You (Profit Hunter)

Jun 2, 2021

Get ready to profit from a massive stimulus that you've never seen before.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 11, 2021 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS